Actively Recruiting
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Led by Hunan Cancer Hospital · Updated on 2026-04-02
121
Participants Needed
6
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.
CONDITIONS
Official Title
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary participation with informed consent
- Age 18 years or older
- Pathologically confirmed non-small cell or small cell lung cancer
- Indication for thoracic radiotherapy with esophagus within 1 cm of the planned treatment volume
- Prescription radiation dose of 60-70 Gy once daily, 45 Gy twice daily with intervals over 6 hours, or 45 Gy once daily
- Ability to take food orally in a normal way
- ECOG performance status score of 0-1
- Lung volume receiving more than 20 Gy radiation does not exceed 30% of total lung volume
- Expected survival longer than 3 months
- Laboratory tests within specified limits: ANC ≥ 1.5 × 10^9/L; platelets ≥ 80 × 10^9/L; hemoglobin ≥ 90 g/L; TBIL ≤ 1.5 × ULN; ALT and AST ≤ 2 × ULN; BUN and creatinine ≤ 1.5 × ULN; creatinine clearance ≥ 50 mL/min
- Agreement to use reliable contraception during study for women of childbearing potential, men, and partners of men
You will not qualify if you...
- Prior thoracic radiotherapy
- Suspected or confirmed tumor invasion of the esophagus
- Presence of other primary tumors
- History of esophageal or gastric cancer, or prior esophageal surgery
- Active reflux esophagitis
- Current regular use of immunonutrition supplements like Oral Impact®
- Severe cardiovascular, cerebrovascular, liver, or kidney diseases
- Women who are pregnant, breastfeeding, or planning pregnancy during the study
- Active autoimmune diseases requiring treatment
- Positive for HIV or AIDS
- Any medical, psychiatric, or social condition that may affect safety, consent, cooperation, or study evaluation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
2
Third Xiangya Hospital, Central South University
Changsha, Hunan, China, 410013
Actively Recruiting
3
Xiangya Hospital of Central South University,
Changsha, Hunan, China
Actively Recruiting
4
The First People's Hospital of Chenzhou
Chenzhou, Hunan, China
Actively Recruiting
5
The Fisrt Affilated Hospital of University of South China
Hengyang, Hunan, China, 421001
Actively Recruiting
6
Yueyang Central Hospital
Yueyang, Hunan, China
Actively Recruiting
Research Team
H
Huai Liu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here